Key result
Adding Visken to methyldopa reduces supine systolic BP ~18 mm Hg, allowing dose reduction.
Why the study?
Does adding pindolol to methyldopa therapy improve blood pressure control and reduce methyldopa requirements in patients with poorly controlled hypertension?
Does adding pindolol to methyldopa therapy improve blood pressure control and reduce methyldopa requirements in patients with poorly controlled hypertension?
Adding pindolol to methyldopa in poorly controlled hypertensive patients effectively reduces blood pressure and allows for a significant reduction in methyldopa dosage.
No takes yet. Share an insight, caveat, or question.
May support adjunctive pindolol to reduce methyldopa dose in uncontrolled hypertension; leaves open need for randomized confirmation.
Jane E. Murphy (1976) studied Hypertension (n=50). Visken vs. Baseline was evaluated on Supine blood pressure. Addition of Visken to methyldopa therapy for 12 weeks reduced supine blood pressure from 177/108 mm Hg to 159/96 mm Hg and allowed a reduction in methyldopa dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: